Ms Delphine Davan-Gatti United States

Covalent Development facilite le développement de votre portefeuille clients et de votre chiffre d'affaires en Amérique du Nord. Nous sommes spécialisés dans la vente de services complexes et innovants à l'Industrie Pharmaceutique et Cosmétique.

Based in Central New Jersey, Covalent Development offers to develop US business activities of Biotech companies.  
The state of New Jersey is home to more than 300 biotechnology companies and 20 pharmaceutical and medical technology firms (17 out of the world’s top 20 have major facilities in the state). This incredible concentration offers extraordinary opportunities to develop your business.  
New York, Boston, Washington DC, North Carolina and Philadelphia are close and there is only 3 hours of time difference with West Coast. It makes things easier to reach your prospects and clients!

----

Basée dans le centre du New Jersey, Covalent Development propose de développer vos activités aux Etats-Unis. 
L'état du New Jersey héberge plus de 300 entreprises de biotechnologie ainsi que 20 sociétés pharmaceutiques et médicales (17 du top 20 sont implantées dans l'état). C'est une localisation idéale pour développer votre business. 
New York, Boston, Washington DC, la Caroline du Nord et Philadelphia sont proches et il n'y a que 3 heures de décalage horaire avec la côte ouest. De quoi faciliter les échanges avec vos prospects et clients ! 


Ms Delphine Davan-Gatti
Covalent Development
Owner, Founder 

Mr Luke Dean United States

ICV hosts events which bring together the CEOs of private and public growth companies and family offices and fund investors in a collaborative and safe environment. In one year, our events grew sixfold in attendance, without advertising; we grew because of the quality of the people. 

Our experience as investors attending conferences and group formats in the financial industry has shown us that most company outreach events have the same feel. Overcrowded with those that inhibit the networking process and rapid fire presentations by CEOs who then race off with little to no substantive interaction after the fact, these experiences seem to leave investor attendees with unanswered questions about the top person in command, the investment opportunity, or why it can’t be done better. We believe it can. 

ICV’s response to these engagement gaps at most investor events have been to create a novel medium for both companies AND investors. Whilst presentations remain at the core of the agenda, the pace is much more relaxed and designed to allow investor attendees to get to know management and fellow investors without the distraction of service provider booths and sponsorship talks. The focus shifts exclusively to listening to company presentations while building rapport and relationships through group Q&A and due diligence sessions following each CEO presentation. Companies are carefully curated for quality, with most sourced by investor attendees or based on their investment criteria, to ensure that the attendees are seeing the kind and quality of company they seek. 

No more ten minute speed dating with ICV, we give investors two days in an intimate environment to ask all their questions and to see company management in many different settings. When it comes to investing, ICV believes that with a more complete picture of a company and especially its leaders, investors can feel more confident that their returns will be more secure.

Specialties

Events, Retreats, Roadshows, Research

ICV, Inc.
Analyst 

Miss Shanaya Deboo United States

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines, as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Website:
www.pfizer.com
Miss Shanaya Deboo
Pfizer
Director, Commercial Development 

Mr Adrien Decque France

CLEVEXEL Pharma invests its teams' know-how to catalyze innovative drug development projects and ensure their attractiveness on the market.

We are an integrated, one-stop-shop solution for the co-development of promising new therapeutic compounds. We partner with inventors to boost the development of their product from proof-of-concept in an animal model to proof-of-concept in human. The project is then outlicensed to a pharmaceutical company for Phase III and Market Access.

CleveXel Pharma
Coordinateur scientifique 

Dr Jack DeHovitz United States

Formally known as The State University of New York Health Science Center at Brooklyn—but better known to our patients and Brooklyn neighbors as SUNY Downstate Medical Center—we are older than the Brooklyn Bridge. We trace our roots back to 1860, when a school of medicine was founded at the Long Island College Hospital. The new college’s faculty revolutionized medical education in this country by bringing the teaching of medicine to the hospital bedside, thus rejecting the idea that physicians should be trained exclusively in university lecture halls.

Nobel Prize Winner in Medicine
Dr. Robert Furchgott

Today, SUNY Downstate is one of the nation’s leading urban medical centers. SUNY Downstate comprises a College of MedicineCollege of Health Related ProfessionsCollege of NursingSchool of Graduate StudiesSchool of Public Health, and University Hospital of Brooklyn.

The quality of our education, research, and patient care programs was confirmed with the awarding of theNobel Prize in Medicine to Dr. Robert Furchgott, a member of our School of Graduate Studies faculty since 1956. Dr. Furchgott’s identification of nitric oxide as a signalling molecule important in vascular health has revolutionized care for heart, stroke, impotence, and other diseases.

As the only academic medical center in Brooklyn, we serve a large population–over 2.3 million people–and one that is among the most diverse in the world. We are also an engine of opportunity for students interested in pursuing careers in health care. Many of our students are the first in their families to attend college.

More physicians who practice medicine in New York City received their training at our College of Medicine than any other medical center in the country. Nationally, our medical school ranks seventh in the number of graduates who are now engaged in academic medicine. Here in Brooklyn, our impact is even greater. We have trained nearly half of all doctors practicing in a number of specialty areas.

Our College of Health Related Professions and College of Nursing also play a unique role in the borough and the city. We have the oldest midwifery program in the country, and we recently made history again by establishing a joint program between the two colleges that trains midwives who are not nurses. The College of Nursing is particularly proud of its role in educating minority students. Approximately three-fourths of the students are minority-group members, and many are recent immigrants.

University Hospital of Brooklyn is the borough’s only hospital located at an academic medical center. As such, it offers the most advanced and comprehensive care in Brooklyn. Many of its physicians are regularly rated among the best in New York City. Some are known throughout the world.

SUNY Downstate Medical Center enters the new century with a renewed dedication to serving the people of Brooklyn through its three-fold mission of education, research, and patient care.

SUNY Downstate
Professor 

Rémi DELANSORNE France

HYBRIGENICS Hybrigenics is a biopharmaceutical company involved in the discovery and the development of new anticancer drugs. Industry sectors Biotech Therapeutics Area Oncology
Your innovative solution

Hybrigenics is developing inecalcitol, a vitamin D receptor agonist, characterized by enhanced activities against cancer cell proliferation and much reduced toxicity on blood calcium levels as compared to calcitriol, the active form of vitamin D. Therefore, inecalcitol can be given at high daily oral doses which exert cytostatic effects on tumors. 

Which problem are you solving ?

Acute myeloid leukemia (AML) has the worse prognosis of all types of leukemias (<25% 5-year survival). Furthermore, elderly or frail AML patients cannot support standard induction chemotherapy and are eligible only to treatment with either decitabine or azacytidine, two hypo-methylating agents. The goal is to increase overall survival of these desperate patients by adding daily oral inecalcitol to hypo-methylating therapy.

Target market segments

Pharmaceutical products / anticancer agents / hematological malignancies / small chemical drugs /

Key value proposition

Orphan drug status already granted for AML in US and EU / Excellent tolerance in patients / convenient daily oral dosing favoring compliance / Strong proof of principle in animal AML models

HYBRIGENICS
CEO 

Hervé DEMAIS France

Olmix is a marine biotechnology specialist providing algae-based therapeutic solutions in CNS, oncology and immunology.

AN UNIQUE INNOVATIVE SOLUTION

Olmix group has developed specific knowledge and technologies to extract and select algal molecules of interest for animal and plant health. Some of these molecules can also be beneficial for human health and one of them has been identified as a potential antidepressant for humans.                                             

We have found in algae a new antidepressant molecule which from what we know at the moment provide beneficial effects against depression without any undesirable side effect.

 

KEY VALUE PROPOSITION

  • Efficient Natural solution
  • No side effect
  • Easy to produce

TARGET MARKET SEGMENTS

  • Central Nervous system             
  • Antidepressant
  • Other applications and compounds in oncology and immunology

 

TARGET PARTNERS

  • Co-development partners with interest in described therapeutic areas
  • Investors (Corporate funds, VC...)
OLMIX Group
Scientific Advisor 

Jean Francois DENIS France

AMA, 1 in 10 companies certified "Glass Partner" by Google worldwide, provides mobile and hands-free tele-expertise solutions on smart glasses, mainly in the medical fields. Industry sectors E_health Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dermatology
Gastroenterology / Hepatology
Orthopedics/Orthopedic Surgery
Pediatrics/Neonatology
Your innovative solution


Hands-free, mobile audio-video connection on smart glasses through a HIPAA exchange platform allowing the physician to communicate with the patient and nurse, permitting synchronous tele-consultations. Doctors can take pictures remotely, select areas within the photo to highlight, comment on and transfer to the nurse and patient file.

Which problem are you solving ?

-TELEMEDICINE: AMA's solution brings healthcare expertise to patients, eliminating geographical constraints and improving quality care and patient comfort. - FINANCIAL challenges: reduces transport, hospitalisation costs and time consumption. - EMERGENCY: fast intervention, doubt removal, orientation to best-fitting hospital - E-LEARNING and mentoring: Live and personalised advice and guidance during training/interventions

Target market segments

Emergency 1 / Ambulances 2 / Nursing homes 3 / E-training 4

Key value proposition

Mobility 1 / Hands-free 2 / Videoconferencing (audio - video exchanges) 3 / Efficient (cost and time saving) 4

Contacts:

  • Jean-François DENIS, VP Sales
  • Anne-Fleur ANDRLE, Business Development US

AMA
VP sales 

Chirag Desai United States

BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. We offer a comprehensive test list focusing on molecular diagnostics, anatomical pathology, genetics, and women’s health. Moreover, through its GeneDx subsidiary, BioReference has an international presence in more than 50 countries around the world. 

Our client retention is unparalleled in the industry because we are much more than just the provider of quality diagnostics. We have grown primarily as a result of our differentiating business model which is both physician-centric – providing superior service and support – and clinically relevant – providing innovative and disruptive technology to improve patient outcomes. What makes us different from other labs is the added value we bring through personal attention and professional support and the effort we make to understand our clients’ needs. Our success comes from helping clinicians deliver premium services to the patients in their care – through a full menu of cost–conscious testing options and cutting edge technologies with clinically–relevant results, all in a medically and fiscally responsible manner. 

In addition, BioReference has pioneered the development of business solutions for our clients, providing data and analytics to help them operate at their fullest potential. 

The Laboratory services multiple markets through several specialized business units, each with its own dedicated sales team and highly-trained support personnel. These include women’s health, oncology, genetics and a lab division focused exclusively on the nation’s expanding Spanish-speaking populations.

Specialties

Clinical Diagnostics, Oncology, Women's Health, Genetic Testing

BioReference Laboratories

Alexandre Detappe France

Nano-H AGuIX: the nanomedicine solution to improve MRI-guided radiation therapy Industry sectors Biotech Therapeutics Area Oncology
Your innovative solution

AGuIX is a Gadolinium nanoparticle, injectable by IV, that improve MRI-guided radiation therapy, allowing personalized medicine for an optimize radiation treatment. Eliminated by the kidneys without toxicity, AGuIX allow within a single injection tumor delineation and enhancement of treatment efficacy.

Which problem are you solving ?

Radiation therapy can generates toxicity in the organs surrounding the tumor and CT images are not specific in soft tissue areas. AGuIX enhance the tumor delineation under MRI by enhancing the contrast and boost the effect of the radiation in the tumor. AGuIX can enhance treatment efficacy and might be use to reduce the planned dose to spare the healthy organs.

Target market segments

1/ Radiation Oncology 2/ Contrast Agent 3/ Compagnon diagnosis

Key value proposition

1/ Radiosensitizer 2/ MRI agent 3/ Personalized medicine / Various injection mode

Nano-H
Engineer R&D